TelyRx’s September-quarter loss was twice the expected amount, marking its third straight quarterly earnings miss. Revenue grew quickly, but losses and cash use remain key concerns for investors.
TelyRx Holdings Inc. (TSX: TELY) reported a fiscal third-quarter 2026 loss of C$0.08 per share for the period ended September 30, compared with an estimated loss of C$0.04. That’s a 100% miss against the estimate. The results also show strong revenue growth alongside a wider operating loss. You can follow TELY.TO’s figures and coverage on the TELY stock page.
Recent earnings trend
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$60.89M
52W high
$4.25
52W low
$2.00
1W change
-6.53%
Analyst Price Targets
Based on analyst covering TELY · as of Sep 17, 2026
Wall Street analysts forecast TELY stock price to rise 162.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+162.0% Upside
Current Price
C$2.29
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
64.8%
Annualized
90-Day Vol
83.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.92
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.16 | C$1.73 – C$2.70 |
| 60 trading days | C$2.03 | C$1.48 – C$2.79 |
| 90 trading days | C$1.92 | C$1.30 – C$2.82 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-05 | -0.0800 | -0.0400 | -100.0% |
| 2026-06-30 | 2026-08-10 | -0.1200 | -0.0600 | -100.0% |
| 2026-03-31 | 2026-05-12 | -0.2900 | -0.0300 | -866.7% |
Investor takeaway: TelyRx faces a growth-versus-profitability challenge. Supplemental company results show revenue rose 88% year over year to US$23.1 million, while the operating loss widened. The company also recorded US$9.4 million in operating cash outflow over the first nine months. It has missed earnings estimates in each of the past three comparable quarters. The next results will show whether growth is helping narrow losses and improve cash flow.
C$0.08 loss per share
TelyRx reported a loss of C$0.08 per share, compared with an estimated loss of C$0.04—a 100% miss. The company has missed earnings estimates in all three comparable quarters provided. That record is worth considering alongside revenue, operating losses and cash flow, especially since the available estimates and results are limited.
Bull case
Revenue rose 88% year over year, suggesting TelyRx is growing its business. In October, the company also announced a women’s-health offering, giving it another potential source of sales. The next-quarter consensus estimate is US$30.30 million in revenue, but it comes from just one analyst. Analyst price-target data shows an average target of C$6.00, compared with the last close of C$2.29. That’s a comparison, not a guarantee or a formal rating for the Canadian-listed shares.
Bear case
TelyRx is still losing money. The supplied fundamentals show trailing earnings per share of -C$0.79 and a profit margin of -19.36%. Its latest earnings result missed expectations, following misses in the two prior comparable quarters. Supplemental results show an operating loss of US$2.7 million, up from US$0.9 million a year earlier, and US$9.4 million in operating cash outflow over the first nine months. The shares also closed below their 50-day and 200-day moving averages. At C$2.29, the last close was nearer the 52-week low of C$2.00 than the high of C$4.25.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
